Shares of The Beauty Health Company (NASDAQ:SKIN – Get Free Report) have been given an average recommendation of “Hold” by the seven analysts that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $1.3750.
A number of research analysts have weighed in on the stock. Zacks Research lowered shares of Beauty Health from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 20th. TD Cowen cut their price target on Beauty Health from $1.00 to $0.90 and set a “hold” rating for the company in a report on Wednesday, August 12th. Weiss Ratings downgraded Beauty Health from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 23rd. Roth Capital reissued a “buy” rating and set a $2.00 price objective (down from $2.50) on shares of Beauty Health in a research note on Wednesday, May 20th. Finally, Canaccord Genuity Group lowered their price objective on Beauty Health from $1.50 to $1.00 and set a “hold” rating on the stock in a research note on Friday, May 1st.
Read Our Latest Research Report on SKIN
Beauty Health Price Performance
Beauty Health (NASDAQ:SKIN – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.02) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.02). Beauty Health had a negative net margin of 9.79% and a negative return on equity of 47.83%. The firm had revenue of $72.11 million for the quarter, compared to analyst estimates of $74.45 million. On average, equities analysts predict that Beauty Health will post -0.16 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Beauty Health
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Bank of America Corp DE raised its position in Beauty Health by 19.2% in the first quarter. Bank of America Corp DE now owns 106,242 shares of the company’s stock valued at $95,000 after purchasing an additional 17,088 shares during the period. Renaissance Technologies LLC boosted its position in shares of Beauty Health by 29.6% during the first quarter. Renaissance Technologies LLC now owns 283,791 shares of the company’s stock worth $253,000 after buying an additional 64,900 shares during the period. Capricorn Fund Managers Ltd purchased a new position in shares of Beauty Health during the first quarter worth $17,270,000. Diversified Trust Co acquired a new stake in shares of Beauty Health in the first quarter valued at $25,000. Finally, Invesco Ltd. grew its stake in shares of Beauty Health by 65.4% in the fourth quarter. Invesco Ltd. now owns 69,422 shares of the company’s stock valued at $96,000 after buying an additional 27,453 shares in the last quarter. Hedge funds and other institutional investors own 93.26% of the company’s stock.
About Beauty Health
Beauty Health Company (NASDAQ: SKIN) is a U.S.-based consumer wellness and beauty enterprise that integrates device-based and product-based offerings across skin, body and hair wellness categories. The company operates a portfolio of established brands that blend professional and at-home solutions, focusing on innovative formulations and technologies to address a range of beauty and self-care needs. Through its proprietary e-commerce platforms and strategic retail partnerships, Beauty Health seeks to deliver premium experiences and tangible results to a global customer base.
Beauty Health’s brand portfolio includes Sol de Janeiro, known for its award-winning Brazilian Bum Bum Cream body care collection; Elemis, a U.K.-originated professional skin care line distributed in spas and skincare clinics; NuFACE and Dermaflash, two at-home beauty device brands specializing in microcurrent facial toning and gentle exfoliation respectively; and Nutrafol, a legal-strength hair wellness supplement clinically designed to support hair growth.
Featured Stories
- Five stocks we like better than Beauty Health
- The Metals Company’s Big Bet Now Comes Down to a License
- OneSpaWorld Keeps Turning Cruise Demand Into Record Earnings
- Meta and Tesla Are Rebounding From Oversold Levels—Now What?
- AMG’s Alternatives Boom Powers Record Growth
Receive News & Ratings for Beauty Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beauty Health and related companies with MarketBeat.com's FREE daily email newsletter.
